Product Center
The kickoff meeting for clinical research on the immunogenicity and safety of quadrivalent influenza virus subunit vaccine for children with nephrotic syndrome was successfully held
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-12-25
- Views:
(Summary description)Recently, the clinical launch meeting for the immunogenicity and safety of quadrivalent influenza virus subunit vaccine for children with nephrotic syndrome, in collaboration with Ab&B Bio-Tech Co.,Ltd（Ab&B Bio） was successfully held at the research site in Guangdong. This clinical study is sponsored and conducted by Guangzhou Women and Children's Medical Center as the core research unit, aiming to provide evidence-based influenza vaccination for children with nephrotic syndrome as a special group, in order to reduce their risk of influenza virus infection and severe infection.
The kickoff meeting for clinical research on the immunogenicity and safety of quadrivalent influenza virus subunit vaccine for children with nephrotic syndrome was successfully held
(Summary description)Recently, the clinical launch meeting for the immunogenicity and safety of quadrivalent influenza virus subunit vaccine for children with nephrotic syndrome, in collaboration with Ab&B Bio-Tech Co.,Ltd（Ab&B Bio） was successfully held at the research site in Guangdong. This clinical study is sponsored and conducted by Guangzhou Women and Children's Medical Center as the core research unit, aiming to provide evidence-based influenza vaccination for children with nephrotic syndrome as a special group, in order to reduce their risk of influenza virus infection and severe infection.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-12-25 09:46
- Views:
Recently, the clinical launch meeting for the immunogenicity and safety of quadrivalent influenza virus subunit vaccine for children with nephrotic syndrome, in collaboration with Ab&B Bio-Tech Co.,Ltd（Ab&B Bio） was successfully held at the research site in Guangdong. This clinical study is sponsored and conducted by Guangzhou Women and Children's Medical Center as the core research unit, aiming to provide evidence-based influenza vaccination for children with nephrotic syndrome as a special group, in order to reduce their risk of influenza virus infection and severe infection.
At the same time, the conduct of this clinical study is also an innovative exploration of the medical prevention integration model, aiming to jointly promote disease prevention and control, improve medical service levels and medical technology capabilities, minimize the occurrence of health problems, control the deterioration of health problems in a targeted manner, improve the suitability and effectiveness of medical and health services, and achieve the goal of putting health at the center.
Nephrotic syndrome is the most common glomerular disease among children. According to the Evidence based Guidelines for Diagnosis and Treatment of Hormone Sensitive, Recurrent/Dependent Nephrotic Syndrome in Children, the annual incidence rate of children in the world is 1.15-16.90/100000. Based on its pathophysiological characteristics and immunosuppressive treatment principles, influenza virus infection increases the difficulty and recurrence of this type of disease. For children with nephrotic syndrome, their immune function is impaired due to long-term use of glucocorticoids and immunosuppressants. According to data from Guangzhou Women and Children's Medical Center in 2023, the incidence of severe cases of kidney syndrome combined with influenza is as high as 43.67%, with a significantly higher severity rate of 3% to 5% compared to normal children. Additionally, the recurrence rate of urinary protein after infection is as high as 56.8%. Therefore, it is particularly important to strengthen influenza prevention for children with nephrotic syndrome. At present, there is a lack of research on the vaccination of children with nephrotic syndrome with influenza vaccine both domestically and internationally, and further exploration is needed on the safety conditions and effective plans for their vaccination with influenza virus vaccine.
The quadrivalent influenza virus subunit vaccine HRK-X its unique subunit production process technology, ensures that the effective antigen components (hemagglutinin HA and neuraminidase NA) have a content of over 85%. Multiple quality standards are higher than those of the Chinese and European Pharmacopoeia standards, reaching the international advanced level, ensuring vaccine safety while also exhibiting good immunogenicity. It is more suitable for frail populations such as chronic disease patients to receive vaccination.
The integration of medicine and prevention is the fundamental path to establish a high-quality and efficient health service system with Chinese characteristics, and it is also an important measure to continuously promote the implementation of the Healthy China strategy. Health management services based on the integration of medicine and prevention are an effective way to ensure that all people enjoy the necessary, high-quality, and affordable health services such as prevention, treatment, rehabilitation, and health promotion.
Relevant information
-
Ab&B Bio and Yither Bio have both obtained qualification certification!Recently, Ab&B Bio-Tech Co.,Ltd（Ab&B Bio） and its subsidiary Yither biotech (Shanghai) Co., Ltd (Yither Bio) have been recognized as Jiangsu Province's specialized and innovative small and medium-sized enterprises and national high-tech enterprises, respectively. - The kickoff meeting for clinical research on the immunogenicity and safety of quadrivalent influenza virus subunit vaccine for children with nephrotic syndrome was successfully held 12-25
- Influenza virus subunit vaccine (adjuvant) IND application approved 10-30
- The application for the marketing of trivalent influenza virus subunit vaccine has been accepted! 10-08
- Breaking through bottleneck technology, significant progress has been made in the research and development of new adjuvants 08-26
Have a project？Get a touch!
Caring for life, protecting health, and making global technological innovation vaccines are the mission of Ab&B Bio
Contact
E-mail:info@abbbio.com.cn
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
